RNAi for Therapeutic

RNAi for Therapeutic Comprehensive Study by Type (Small interfering RNAs (siRNA), Short hairpin RNAs (shRNA)), Application (Neurodegenerative Disease, Cardiovascular Disease, Viral Infection, RNAi-Based Tumor Treatment, Cancer), End User (Hospitals, Laboratories, Clinical Research Centers, Others) Players and Region - Global Market Outlook to 2027

RNAi for Therapeutic Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About RNAi for Therapeutic
RNAi also known as Post-Transcriptional Gene Silencing (PTGS) is a conserved biological response to double-stranded RNA that mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids, and regulates the expression of protein-coding genes. RNA is a natural biological process that regulates gene expression by “interfering” with messenger RNA (mRNA), which carries DNA’s instructions for making new proteins. RNAi therapeutics is an innovative new class of medicines based on RNA interference (RNAi)—a breakthrough discovery in understanding how genes are regulated naturally within cells.

AttributesDetails
Study Period2017-2027
Base Year2021
UnitValue (USD Million)


The market for RNAi for Therapeutic is highly competitive with several global as well as local players in the market. The global players are trying various strategies such as product innovation and using various marketing strategies to gain a higher market share. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global RNAi for Therapeutic market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Ionis Pharmaceuticals (United States), Moderna (United States), Vir Biotechnology, Inc. (United States), Alnylam Pharmaceuticals (United States), BOC Sciences (United States), Akcea Therapeutics (United States), Abogen Biosciences (China), Arrowhead Pharmaceuticals (United States), laronde therapeutics (United States) and Sarepta Therapeutics (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Nutcracker Therapeutics (United States), Deep Genomics (Canada), Sirnaomics (United States), Gotham Therapeutics (United States), Quark Pharmaceuticals (Israel), Gradalis (United States), CureVac (Germany) and BioNTech (Germany).

Segmentation Overview
AMA Research has segmented the market of Global RNAi for Therapeutic market by Type (small interfering RNAs (siRNA) and short hairpin RNAs (shRNA)), Application (Neurodegenerative Disease, Cardiovascular Disease, Viral Infection, RNAi-Based Tumor Treatment and Cancer) and Region.



On the basis of geography, the market of RNAi for Therapeutic has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End User, the sub-segment i.e. Hospitals will boost the RNAi for Therapeutic market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological Penetration and New Innovation in RNAi for Therapeutic

Market Growth Drivers:
Surge in Demand in Laboratories Gene Interfering in Genome, Demand in Therapy of Muscular Degeneration, Rising Demand in Treatment of Respiratory Infections and Rising demand in New drug and Medicine development

Challenges:
Lack of Acceptance in Clinical Practice Due To Low Stability And Drug Delivery, Lack of Technological Standards for RNAi Therapeutic, Complicated and Complex Therapy Procedure and Lack of Skilled Professional for RNAi Therapeutic

Restraints:
Lack Of Delivering An Efficacious Doses Of The RNAi-Triggering Molecules To The Target Tissue

Opportunities:
Growth in Medical Research and Development and Continuous Development in Healthcare Infrastructure

Market Leaders and their expansionary development strategies
On 3 April 2020, Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc announced an expansion of their existing collaboration to include the development and commercialization of RNAi therapeutics targeting SARS-CoV-2, the virus that causes the disease COVID-19. Under the agreement, the companies will utilize Alnylam’s recent advances in lung delivery of novel conjugates of siRNA – the molecules that mediate RNAi – together with Vir’s infectious disease expertise and established capabilities, to bring forward one or more siRNAs to treat SARS-CoV-2 and potentially other coronaviruses as well. The collaboration will focus on development of siRNAs that Alnylam recently identified that target highly conserved regions of coronavirus RNAs.
On 28 December 2020, BOC RNA announced the expansion of its existing cooperation scope, including the development and commercialization of RNAi therapeutic drugs. The company will use its latest progress in targeted delivery of siRNA drugs and its established capabilities to deepen the development of RNAi drugs for tumors and neurological diseases.


Key Target Audience
RNAi for Therapeutic, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • small interfering RNAs (siRNA)
  • short hairpin RNAs (shRNA)
By Application
  • Neurodegenerative Disease
  • Cardiovascular Disease
  • Viral Infection
  • RNAi-Based Tumor Treatment
  • Cancer
By End User
  • Hospitals
  • Laboratories
  • Clinical Research Centers
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Surge in Demand in Laboratories Gene Interfering in Genome
      • 3.2.2. Demand in Therapy of Muscular Degeneration
      • 3.2.3. Rising Demand in Treatment of Respiratory Infections
      • 3.2.4. Rising demand in New drug and Medicine development
    • 3.3. Market Challenges
      • 3.3.1. Lack of Acceptance in Clinical Practice Due To Low Stability And Drug Delivery
      • 3.3.2. Lack of Technological Standards for RNAi Therapeutic
      • 3.3.3. Complicated and Complex Therapy Procedure
      • 3.3.4. Lack of Skilled Professional for RNAi Therapeutic
    • 3.4. Market Trends
      • 3.4.1. Technological Penetration and New Innovation in RNAi for Therapeutic
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global RNAi for Therapeutic, by Type, Application, End User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global RNAi for Therapeutic (Value)
      • 5.2.1. Global RNAi for Therapeutic by: Type (Value)
        • 5.2.1.1. Small interfering RNAs (siRNA)
        • 5.2.1.2. Short hairpin RNAs (shRNA)
      • 5.2.2. Global RNAi for Therapeutic by: Application (Value)
        • 5.2.2.1. Neurodegenerative Disease
        • 5.2.2.2. Cardiovascular Disease
        • 5.2.2.3. Viral Infection
        • 5.2.2.4. RNAi-Based Tumor Treatment
        • 5.2.2.5. Cancer
      • 5.2.3. Global RNAi for Therapeutic by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Laboratories
        • 5.2.3.3. Clinical Research Centers
        • 5.2.3.4. Others
      • 5.2.4. Global RNAi for Therapeutic Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Australia
          • 5.2.4.2.6. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global RNAi for Therapeutic (Price)
      • 5.3.1. Global RNAi for Therapeutic by: Type (Price)
  • 6. RNAi for Therapeutic: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ionis Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Moderna (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Vir Biotechnology, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Alnylam Pharmaceuticals (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. BOC Sciences (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Akcea Therapeutics (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Abogen Biosciences (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Arrowhead Pharmaceuticals (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Laronde therapeutics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sarepta Therapeutics (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global RNAi for Therapeutic Sale, by Type, Application, End User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global RNAi for Therapeutic (Value)
      • 7.2.1. Global RNAi for Therapeutic by: Type (Value)
        • 7.2.1.1. Small interfering RNAs (siRNA)
        • 7.2.1.2. Short hairpin RNAs (shRNA)
      • 7.2.2. Global RNAi for Therapeutic by: Application (Value)
        • 7.2.2.1. Neurodegenerative Disease
        • 7.2.2.2. Cardiovascular Disease
        • 7.2.2.3. Viral Infection
        • 7.2.2.4. RNAi-Based Tumor Treatment
        • 7.2.2.5. Cancer
      • 7.2.3. Global RNAi for Therapeutic by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Laboratories
        • 7.2.3.3. Clinical Research Centers
        • 7.2.3.4. Others
      • 7.2.4. Global RNAi for Therapeutic Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Australia
          • 7.2.4.2.6. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global RNAi for Therapeutic (Price)
      • 7.3.1. Global RNAi for Therapeutic by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. RNAi for Therapeutic: by Type(USD Million)
  • Table 2. RNAi for Therapeutic Small interfering RNAs (siRNA) , by Region USD Million (2016-2021)
  • Table 3. RNAi for Therapeutic Short hairpin RNAs (shRNA) , by Region USD Million (2016-2021)
  • Table 4. RNAi for Therapeutic: by Application(USD Million)
  • Table 5. RNAi for Therapeutic Neurodegenerative Disease , by Region USD Million (2016-2021)
  • Table 6. RNAi for Therapeutic Cardiovascular Disease , by Region USD Million (2016-2021)
  • Table 7. RNAi for Therapeutic Viral Infection , by Region USD Million (2016-2021)
  • Table 8. RNAi for Therapeutic RNAi-Based Tumor Treatment , by Region USD Million (2016-2021)
  • Table 9. RNAi for Therapeutic Cancer , by Region USD Million (2016-2021)
  • Table 10. RNAi for Therapeutic: by End User(USD Million)
  • Table 11. RNAi for Therapeutic Hospitals , by Region USD Million (2016-2021)
  • Table 12. RNAi for Therapeutic Laboratories , by Region USD Million (2016-2021)
  • Table 13. RNAi for Therapeutic Clinical Research Centers , by Region USD Million (2016-2021)
  • Table 14. RNAi for Therapeutic Others , by Region USD Million (2016-2021)
  • Table 15. South America RNAi for Therapeutic, by Country USD Million (2016-2021)
  • Table 16. South America RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 17. South America RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 18. South America RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 19. Brazil RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 20. Brazil RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 21. Brazil RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 22. Argentina RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 23. Argentina RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 24. Argentina RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 25. Rest of South America RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 26. Rest of South America RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 27. Rest of South America RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 28. Asia Pacific RNAi for Therapeutic, by Country USD Million (2016-2021)
  • Table 29. Asia Pacific RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 30. Asia Pacific RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 31. Asia Pacific RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 32. China RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 33. China RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 34. China RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 35. Japan RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 36. Japan RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 37. Japan RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 38. India RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 39. India RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 40. India RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 41. South Korea RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 42. South Korea RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 43. South Korea RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 44. Australia RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 45. Australia RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 46. Australia RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 47. Rest of Asia-Pacific RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 48. Rest of Asia-Pacific RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 49. Rest of Asia-Pacific RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 50. Europe RNAi for Therapeutic, by Country USD Million (2016-2021)
  • Table 51. Europe RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 52. Europe RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 53. Europe RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 54. Germany RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 55. Germany RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 56. Germany RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 57. France RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 58. France RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 59. France RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 60. Italy RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 61. Italy RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 62. Italy RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 63. United Kingdom RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 64. United Kingdom RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 65. United Kingdom RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 66. Netherlands RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 67. Netherlands RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 68. Netherlands RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 69. Rest of Europe RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 70. Rest of Europe RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 71. Rest of Europe RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 72. MEA RNAi for Therapeutic, by Country USD Million (2016-2021)
  • Table 73. MEA RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 74. MEA RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 75. MEA RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 76. Middle East RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 77. Middle East RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 78. Middle East RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 79. Africa RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 80. Africa RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 81. Africa RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 82. North America RNAi for Therapeutic, by Country USD Million (2016-2021)
  • Table 83. North America RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 84. North America RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 85. North America RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 86. United States RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 87. United States RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 88. United States RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 89. Canada RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 90. Canada RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 91. Canada RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 92. Mexico RNAi for Therapeutic, by Type USD Million (2016-2021)
  • Table 93. Mexico RNAi for Therapeutic, by Application USD Million (2016-2021)
  • Table 94. Mexico RNAi for Therapeutic, by End User USD Million (2016-2021)
  • Table 95. RNAi for Therapeutic: by Type(USD/Units)
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. RNAi for Therapeutic: by Type(USD Million)
  • Table 107. RNAi for Therapeutic Small interfering RNAs (siRNA) , by Region USD Million (2022-2027)
  • Table 108. RNAi for Therapeutic Short hairpin RNAs (shRNA) , by Region USD Million (2022-2027)
  • Table 109. RNAi for Therapeutic: by Application(USD Million)
  • Table 110. RNAi for Therapeutic Neurodegenerative Disease , by Region USD Million (2022-2027)
  • Table 111. RNAi for Therapeutic Cardiovascular Disease , by Region USD Million (2022-2027)
  • Table 112. RNAi for Therapeutic Viral Infection , by Region USD Million (2022-2027)
  • Table 113. RNAi for Therapeutic RNAi-Based Tumor Treatment , by Region USD Million (2022-2027)
  • Table 114. RNAi for Therapeutic Cancer , by Region USD Million (2022-2027)
  • Table 115. RNAi for Therapeutic: by End User(USD Million)
  • Table 116. RNAi for Therapeutic Hospitals , by Region USD Million (2022-2027)
  • Table 117. RNAi for Therapeutic Laboratories , by Region USD Million (2022-2027)
  • Table 118. RNAi for Therapeutic Clinical Research Centers , by Region USD Million (2022-2027)
  • Table 119. RNAi for Therapeutic Others , by Region USD Million (2022-2027)
  • Table 120. South America RNAi for Therapeutic, by Country USD Million (2022-2027)
  • Table 121. South America RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 122. South America RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 123. South America RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 124. Brazil RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 125. Brazil RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 126. Brazil RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 127. Argentina RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 128. Argentina RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 129. Argentina RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 130. Rest of South America RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 131. Rest of South America RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 132. Rest of South America RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 133. Asia Pacific RNAi for Therapeutic, by Country USD Million (2022-2027)
  • Table 134. Asia Pacific RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 135. Asia Pacific RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 136. Asia Pacific RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 137. China RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 138. China RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 139. China RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 140. Japan RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 141. Japan RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 142. Japan RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 143. India RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 144. India RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 145. India RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 146. South Korea RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 147. South Korea RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 148. South Korea RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 149. Australia RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 150. Australia RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 151. Australia RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 152. Rest of Asia-Pacific RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 153. Rest of Asia-Pacific RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 154. Rest of Asia-Pacific RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 155. Europe RNAi for Therapeutic, by Country USD Million (2022-2027)
  • Table 156. Europe RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 157. Europe RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 158. Europe RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 159. Germany RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 160. Germany RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 161. Germany RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 162. France RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 163. France RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 164. France RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 165. Italy RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 166. Italy RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 167. Italy RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 168. United Kingdom RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 169. United Kingdom RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 170. United Kingdom RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 171. Netherlands RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 172. Netherlands RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 173. Netherlands RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 174. Rest of Europe RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 175. Rest of Europe RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 176. Rest of Europe RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 177. MEA RNAi for Therapeutic, by Country USD Million (2022-2027)
  • Table 178. MEA RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 179. MEA RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 180. MEA RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 181. Middle East RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 182. Middle East RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 183. Middle East RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 184. Africa RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 185. Africa RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 186. Africa RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 187. North America RNAi for Therapeutic, by Country USD Million (2022-2027)
  • Table 188. North America RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 189. North America RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 190. North America RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 191. United States RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 192. United States RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 193. United States RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 194. Canada RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 195. Canada RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 196. Canada RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 197. Mexico RNAi for Therapeutic, by Type USD Million (2022-2027)
  • Table 198. Mexico RNAi for Therapeutic, by Application USD Million (2022-2027)
  • Table 199. Mexico RNAi for Therapeutic, by End User USD Million (2022-2027)
  • Table 200. RNAi for Therapeutic: by Type(USD/Units)
  • Table 201. Research Programs/Design for This Report
  • Table 202. Key Data Information from Secondary Sources
  • Table 203. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global RNAi for Therapeutic: by Type USD Million (2016-2021)
  • Figure 5. Global RNAi for Therapeutic: by Application USD Million (2016-2021)
  • Figure 6. Global RNAi for Therapeutic: by End User USD Million (2016-2021)
  • Figure 7. South America RNAi for Therapeutic Share (%), by Country
  • Figure 8. Asia Pacific RNAi for Therapeutic Share (%), by Country
  • Figure 9. Europe RNAi for Therapeutic Share (%), by Country
  • Figure 10. MEA RNAi for Therapeutic Share (%), by Country
  • Figure 11. North America RNAi for Therapeutic Share (%), by Country
  • Figure 12. Global RNAi for Therapeutic: by Type USD/Units (2016-2021)
  • Figure 13. Global RNAi for Therapeutic share by Players 2021 (%)
  • Figure 14. Global RNAi for Therapeutic share by Players (Top 3) 2021(%)
  • Figure 15. Global RNAi for Therapeutic share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Ionis Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 18. Ionis Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 19. Moderna (United States) Revenue, Net Income and Gross profit
  • Figure 20. Moderna (United States) Revenue: by Geography 2021
  • Figure 21. Vir Biotechnology, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Vir Biotechnology, Inc. (United States) Revenue: by Geography 2021
  • Figure 23. Alnylam Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 24. Alnylam Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 25. BOC Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 26. BOC Sciences (United States) Revenue: by Geography 2021
  • Figure 27. Akcea Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 28. Akcea Therapeutics (United States) Revenue: by Geography 2021
  • Figure 29. Abogen Biosciences (China) Revenue, Net Income and Gross profit
  • Figure 30. Abogen Biosciences (China) Revenue: by Geography 2021
  • Figure 31. Arrowhead Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 32. Arrowhead Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 33. Laronde therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 34. Laronde therapeutics (United States) Revenue: by Geography 2021
  • Figure 35. Sarepta Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 36. Sarepta Therapeutics (United States) Revenue: by Geography 2021
  • Figure 37. Global RNAi for Therapeutic: by Type USD Million (2022-2027)
  • Figure 38. Global RNAi for Therapeutic: by Application USD Million (2022-2027)
  • Figure 39. Global RNAi for Therapeutic: by End User USD Million (2022-2027)
  • Figure 40. South America RNAi for Therapeutic Share (%), by Country
  • Figure 41. Asia Pacific RNAi for Therapeutic Share (%), by Country
  • Figure 42. Europe RNAi for Therapeutic Share (%), by Country
  • Figure 43. MEA RNAi for Therapeutic Share (%), by Country
  • Figure 44. North America RNAi for Therapeutic Share (%), by Country
  • Figure 45. Global RNAi for Therapeutic: by Type USD/Units (2022-2027)
List of companies from research coverage that are profiled in the study
  • Ionis Pharmaceuticals (United States)
  • Moderna (United States)
  • Vir Biotechnology, Inc. (United States)
  • Alnylam Pharmaceuticals (United States)
  • BOC Sciences (United States)
  • Akcea Therapeutics (United States)
  • Abogen Biosciences (China)
  • Arrowhead Pharmaceuticals (United States)
  • laronde therapeutics (United States)
  • Sarepta Therapeutics (United States)
Additional players considered in the study are as follows:
Nutcracker Therapeutics (United States) , Deep Genomics (Canada) , Sirnaomics (United States) , Gotham Therapeutics (United States) , Quark Pharmaceuticals (Israel) , Gradalis (United States) , CureVac (Germany) , BioNTech (Germany)
Select User Access Type

Key Highlights of Report


Oct 2023 246 Pages 85 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
RNAi for Therapeutic Quantitative research analysis
RNAi for Therapeutic Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Ionis Pharmaceuticals (United States), Moderna (United States), Vir Biotechnology, Inc. (United States), Alnylam Pharmaceuticals (United States), BOC Sciences (United States), Akcea Therapeutics (United States), Abogen Biosciences (China), Arrowhead Pharmaceuticals (United States), laronde therapeutics (United States) and Sarepta Therapeutics (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological Penetration and New Innovation in RNAi for Therapeutic" is seen as one of major influencing trends for RNAi for Therapeutic Market during projected period 2021-2027.
The RNAi for Therapeutic market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About RNAi for Therapeutic Report?

Have a Query? Click Here

Other Related Reports

Infection Control Comprehensive Study by Type (Hand Disinfectants, Skin Disinfectants, Instrument Disinfectants, Surface Disinfectants), Application (Hospitals & Clinics, Life Sciences Industry, Medi...
$ 3750
Monoclonal Antibody Based Products Comprehensive Study by Type (Murine, Chimeric, Humanized, Human), Application (Therapeutics, Diagnostics), Diseases Type (Non-communicable Diseases, Infectious Dise...
$ 3800
Disposable Cuvettes Comprehensive Study by Type (Polystyrene, Methacrylate), Capacity (Below 10 ml, 10-20 ml, Above 20 ml), End Use (Chemical, Healthcare & Medical, Food Sector, Environmental Protect...
$ 3450
Neuromodulation Devices Comprehensive Study by Type (Internal Neuromodulation, External Neuromodulation), Application (Depression, Parkinsons Disease, Tremor, Others), End Users (Hospitals, Clinics, ...
$ 3450
Orthobiologics Comprehensive Study by Type (Viscosupplementation Products, DBM, Synthetic Orthobiologics, BMP, Allografts, PRP, BMAC), Application (Fracture Recovery, Spinal Fusion, Soft Tissue Injur...
$ 3450
Maca Extract Comprehensive Study by Type (Raw, Gelatinized), Application (Health Drugs, Healthy Foods, Nutritional Supplements, Others), Uses (Leukemia, Chronic Fatigue Syndrome (CFS), Improving Ener...
$ 3750